MX2017015909A - Uso de la modulacion de trimetilacion de h3k9 (h3k9me3) para aumentar la funcion cognitiva. - Google Patents

Uso de la modulacion de trimetilacion de h3k9 (h3k9me3) para aumentar la funcion cognitiva.

Info

Publication number
MX2017015909A
MX2017015909A MX2017015909A MX2017015909A MX2017015909A MX 2017015909 A MX2017015909 A MX 2017015909A MX 2017015909 A MX2017015909 A MX 2017015909A MX 2017015909 A MX2017015909 A MX 2017015909A MX 2017015909 A MX2017015909 A MX 2017015909A
Authority
MX
Mexico
Prior art keywords
cognitive function
enhancing cognitive
h3k9me3
modulation
h3k9me3 modulation
Prior art date
Application number
MX2017015909A
Other languages
English (en)
Spanish (es)
Inventor
Cotman Carl
Overman Larry
SNIGDHA Shikha
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2017015909A publication Critical patent/MX2017015909A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/548Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Networks Using Active Elements (AREA)
  • Amplifiers (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
MX2017015909A 2015-06-08 2016-06-03 Uso de la modulacion de trimetilacion de h3k9 (h3k9me3) para aumentar la funcion cognitiva. MX2017015909A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562172690P 2015-06-08 2015-06-08
PCT/US2016/035764 WO2016200690A1 (en) 2015-06-08 2016-06-03 USE OF H3K9me3 MODULATION FOR ENHANCING COGNITIVE FUNCTION

Publications (1)

Publication Number Publication Date
MX2017015909A true MX2017015909A (es) 2018-05-07

Family

ID=57504356

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015909A MX2017015909A (es) 2015-06-08 2016-06-03 Uso de la modulacion de trimetilacion de h3k9 (h3k9me3) para aumentar la funcion cognitiva.

Country Status (11)

Country Link
US (5) US10272093B2 (enExample)
EP (2) EP3733188B1 (enExample)
JP (1) JP6851081B2 (enExample)
KR (1) KR102776570B1 (enExample)
CN (1) CN107849061B (enExample)
AU (2) AU2016276172B2 (enExample)
CA (1) CA2988568A1 (enExample)
ES (2) ES2944446T3 (enExample)
IL (1) IL256055B (enExample)
MX (1) MX2017015909A (enExample)
WO (1) WO2016200690A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017015909A (es) * 2015-06-08 2018-05-07 Univ California Uso de la modulacion de trimetilacion de h3k9 (h3k9me3) para aumentar la funcion cognitiva.
CN111032025A (zh) * 2017-06-20 2020-04-17 居里研究所 Suv39h1组蛋白甲基转移酶的抑制剂在癌症联合治疗中的用途
CN108434454B (zh) * 2018-03-16 2019-10-11 大连医科大学 Adar1在缓解认知功能障碍方面的应用
WO2020223475A1 (en) * 2019-05-02 2020-11-05 Board Of Regents, The University Of Texas System Methods and compositions involving tert activating therapies
US20240009203A1 (en) * 2020-08-03 2024-01-11 Cedars-Sinai Medical Center Compositions and methods for treating alzheimer's disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534255B1 (en) * 2003-01-24 2009-05-19 Photothera, Inc Low level light therapy for enhancement of neurologic function
US20060019227A1 (en) 2004-07-22 2006-01-26 Hardwicke Susan B Methods for cognitive treatment
CA2601777A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
EP2026783A2 (en) 2006-06-09 2009-02-25 Wyeth a Corporation of the State of Delaware Method for enhancing cognitive function
JP2009084271A (ja) * 2007-09-07 2009-04-23 Toyama Univ 脳由来神経栄養因子の発現誘導剤および発現誘導方法
NZ593447A (en) * 2008-12-03 2012-12-21 Harvard College Inhibition of hdac2 to promote memory
WO2011109267A1 (en) 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
KR101235256B1 (ko) * 2010-09-13 2013-02-21 서울대학교산학협력단 miRNA를 타겟으로 한 신경퇴행성 질환 치료
EP2909214B1 (en) 2012-10-22 2020-07-22 City of Hope Etp derivatives
CA2909506C (en) * 2013-04-17 2021-04-20 H. Lundbeck A/S Nalmefene for treatment of patients with anxiety disorder
CA3089881C (en) * 2013-11-26 2024-04-02 University Of North Texas Health Science Center At Fort Worth Personalized medicine approach for treating cognitive loss
MX2017015909A (es) * 2015-06-08 2018-05-07 Univ California Uso de la modulacion de trimetilacion de h3k9 (h3k9me3) para aumentar la funcion cognitiva.

Also Published As

Publication number Publication date
EP3733188B1 (en) 2023-01-25
IL256055A (en) 2018-01-31
KR20180014432A (ko) 2018-02-08
US20230057592A1 (en) 2023-02-23
ES2944446T3 (es) 2023-06-21
AU2016276172B2 (en) 2019-07-11
AU2016276172A1 (en) 2018-01-04
EP3733188A1 (en) 2020-11-04
EP3303347A4 (en) 2019-03-06
CN107849061B (zh) 2021-05-14
US20240374608A1 (en) 2024-11-14
US11311551B2 (en) 2022-04-26
WO2016200690A1 (en) 2016-12-15
EP3303347A1 (en) 2018-04-11
CA2988568A1 (en) 2016-12-15
AU2019246902A1 (en) 2019-10-31
US10849910B2 (en) 2020-12-01
US20180228808A1 (en) 2018-08-16
US20210106590A1 (en) 2021-04-15
CN107849061A (zh) 2018-03-27
IL256055B (en) 2022-06-01
US20190209577A1 (en) 2019-07-11
AU2019246902B2 (en) 2021-08-19
ES2807878T3 (es) 2021-02-24
EP3303347B1 (en) 2020-05-06
US10272093B2 (en) 2019-04-30
JP6851081B2 (ja) 2021-03-31
JP2018516940A (ja) 2018-06-28
KR102776570B1 (ko) 2025-03-04

Similar Documents

Publication Publication Date Title
PH12020550857A1 (en) Polycyclic compounds as allosteric shp2 inhibitors
MX2023004037A (es) Compuestos biciclicos como inhibidores alostericos de shp2.
MX2015010921A (es) Compuestos de carbazol utiles como inhibidores de bromodominio.
ZA201807398B (en) Use of glutamate modulating agents with immunotherapies to treat cancer
MX368833B (es) Derivados de quinolina y quinazolina amidas como inhibidores de canales de sodio nav1.8 y el uso de los mismos en el tratamiento del dolor.
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
EA201790737A1 (ru) Комбинированная терапия
MX2015002755A (es) 1,3-dioxanomorfidas y 1,3-dioxanocodidas.
MX2017015909A (es) Uso de la modulacion de trimetilacion de h3k9 (h3k9me3) para aumentar la funcion cognitiva.
MX2023005484A (es) Analogos de carbamoil fenilalaninol y usos de los mismos.
IL242853B (en) Preparations containing dianhydrogalactitol or analogues or derivatives of dianhydrogalactitol for the treatment of sarcoid glioma or an advanced secondary brain tumor
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
GEP20186864B (en) Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
DOP2016000120A (es) Nuevos inhibidores de dgat2
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
MX2017006022A (es) Inhibicion de ornitina aminotransferasa con analogos gaba para el tratamiento de carcinoma hepatocelular.
WO2015100092A3 (en) 7-beta analogs of orvinols
IL259153A (en) Use of proteasome inhibitors to treat ocular disorders
NZ713129A (en) Oxprenolol compositions for treating cancer
SG11202103588WA (en) Use of reboxetine to treat narcolepsy
PH12016500495A1 (en) Compositions for the treatment of hypertension and/or fibrosis
IL291424A (en) Use of dkk-1 inhibitors for treating cancer
IL269641A (en) Preparations and methods for the treatment of complications and disorders related to Factor One and Liebrand
IL285910A (en) Use of vibragron to treat overactive bladder